Multicenter prospective investigation on efficacy and safety of carperitide as a first-line drug for acute heart failure syndrome with preserved blood pressure: COMPASS: Carperitide Effects Observed Through Monitoring Dyspnea in Acute Decompensated Heart Failure Study
- PMID: 18832779
- DOI: 10.1253/circj.cj-07-0760
Multicenter prospective investigation on efficacy and safety of carperitide as a first-line drug for acute heart failure syndrome with preserved blood pressure: COMPASS: Carperitide Effects Observed Through Monitoring Dyspnea in Acute Decompensated Heart Failure Study
Abstract
Background: Recently, vasodilators have been increasingly being recognized as useful for the treatment of acute heart failure syndromes (AHFS). Although carperitide (alpha-human atrial natriuretic peptide) has vasodilatory, diuretic and organ-protective effects, its efficacy and safety for the first-line drug treatment of AHFS have not been reported.
Methods and results: A prospective observational study was performed in AHFS patients with preserved systolic blood pressure (SBP >or=120 mmHg), pulmonary congestion and dyspnea who were receiving carperitide monotherapy. The analysis was conducted in 1,832 patients (male: 52.7%; mean age: 75.1+/-12.7 years). The initial SBP was 151.1+/-25.7 mmHg; 62.0% were diagnosed as having acutely decompensated chronic heart failure and 78.8% were assessed as functional class III-IV according to New York Heart Association classification. Carperitide was administered at an initial dosage of 0.025-0.05 microg x kg(-1) x min(-1) in 50.4% of patients. In 1,524 patients (83.2%), carperitide monotherapy restored the acute phase and improved the degree of dyspnea as assessed using the modified Borg scale. The incidence of adverse drug reactions was 4.64%; the most frequently reported adverse reaction was hypotension (3.55%).
Conclusion: In the present study, following carperitide monotherapy, 83.2% of AHFS patients recovered from the acute phase. Based on these findings, carperitide seems useful for the first-line drug treatment of AHFS in patients with pulmonary congestion and preserved blood pressure.
Similar articles
-
Predictors of responders for low-dose carperitide monotherapy in patients with acute heart failure.Heart Vessels. 2020 Jan;35(1):59-68. doi: 10.1007/s00380-019-01450-w. Epub 2019 Jun 21. Heart Vessels. 2020. PMID: 31227874
-
Differences in hemodynamic responses between intravenous carperitide and nicorandil in patients with acute heart failure syndromes.Heart Vessels. 2013 May;28(3):345-51. doi: 10.1007/s00380-012-0252-7. Epub 2012 Apr 19. Heart Vessels. 2013. PMID: 22526380 Clinical Trial.
-
Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the 'real world' of therapy.Circ J. 2005 Mar;69(3):283-90. doi: 10.1253/circj.69.283. Circ J. 2005. PMID: 15731532 Clinical Trial.
-
Acute heart failure with dyspnoea: initial treatment. Furosemide and trinitrine, despite the lack of a proven survival benefit.Prescrire Int. 2011 Jun;20(117):156-60. Prescrire Int. 2011. PMID: 21678708 Review.
-
[Acute decompensated heart failure].Nihon Rinsho. 2013 Jun;71(6):1035-41. Nihon Rinsho. 2013. PMID: 23855210 Review. Japanese.
Cited by
-
Perceived dyspnea and experience of hospitalized patients with acute decompensated heart failure undergoing an early MObilization protocol with immersive Virtual rEality: MOVE study protocol for a parallel superiority randomized clinical trial.Trials. 2023 Nov 24;24(1):751. doi: 10.1186/s13063-023-07786-z. Trials. 2023. PMID: 38001540 Free PMC article.
-
Neurohumoral Activation in Heart Failure.Int J Mol Sci. 2023 Oct 23;24(20):15472. doi: 10.3390/ijms242015472. Int J Mol Sci. 2023. PMID: 37895150 Free PMC article. Review.
-
An integrated proteomic and transcriptomic signature of the failing right ventricle in monocrotaline induced pulmonary arterial hypertension in male rats.Front Physiol. 2022 Nov 1;13:966454. doi: 10.3389/fphys.2022.966454. eCollection 2022. Front Physiol. 2022. PMID: 36388115 Free PMC article.
-
Natriuretic Peptide-Based Novel Therapeutics: Long Journeys of Drug Developments Optimized for Disease States.Biology (Basel). 2022 Jun 3;11(6):859. doi: 10.3390/biology11060859. Biology (Basel). 2022. PMID: 35741380 Free PMC article. Review.
-
DNA Methylation of the Natriuretic Peptide System Genes and Ischemic Stroke: Gene-Based and Gene Set Analyses.Neurol Genet. 2022 May 11;8(3):e679. doi: 10.1212/NXG.0000000000000679. eCollection 2022 Jun. Neurol Genet. 2022. PMID: 35620136 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous